Business Wire

Reprieve Cardiovascular Completes Enrollment in Randomized Pilot Trial Evaluating First-of-its-Kind Personalized Fluid Management System for Acute Decompensated Heart Failure

MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart ...
Business Wire

First-In-Human Study Demonstrates the Potential of the Reprieve System in Patients with Acute Decompensated Heart Failure

MILFORD, Mass. & FRANKFURT, Germany--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today ...
Morningstar

Reprieve Cardiovascular to Present at the 37th Annual Piper Sandler Healthcare Conference

During the conference, Mr. Pacyna will discuss Reprieve’s recent corporate and clinical milestones, including the ongoing enrollment in the Company’s pivotal FASTR II clinical trial. The presentation ...
TCTMD

Effect of the Reprieve Decongestion System Based on Serum Chloride Levels: A Sub Analysis of the FASTR Randomized Controlled Trial

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...
TCTMD

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS) – The FASTR Trial

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...